Henry Schein at Jefferies Global Healthcare: Strategic Growth Focus

At the Jefferies Global Healthcare Conference 2025, Henry Schein (HSIC) outlined its "BOLD plus one" strategy, targeting high single- to low double-digit earnings growth post-restructuring and aiming for 60% of operating income from high-growth areas by 2027. CEO Stan Bergman and CFO Ron South highlighted the company's focus on optimizing core distribution, leveraging relationships, and digitalizing dentistry and medicine, while also addressing the impact of a prior cyber incident and higher interest rates. Despite stable dental market visits, HSIC is focusing on value and competitive pricing, with $161 million in share repurchases completed in Q1, signaling a robust capital return strategy and confidence in future growth.

Analysis

Henry Schein (NASDAQ:HSIC) presented its "BOLD plus one" strategic vision at the Jefferies Global Healthcare Conference 2025, aiming to derive 60% of operating income from high-growth, high-margin businesses and corporate brands by 2027, and targeting high single-digit to low double-digit earnings growth post-restructuring. Management, led by CEO Stan Bergman and CFO Ron South, acknowledged challenges including market fluctuations, higher interest rates, and a temporary consolidation phase following a cyber incident in October 2023. Despite these, the company reported sales and EPS growth, particularly when excluding PPE sales impacts, and executed $161 million in share repurchases in Q1 2025, surpassing historical trends and signaling confidence. Restructuring initiatives, such as integrating its endodontic business and closing a facility, are expected to yield $75 million to $100 million in cost savings. The collaboration with KKR is focused on enhancing margin and expense management, potentially leveraging KKR's portfolio for improved supplier negotiations. Henry Schein One is advancing cloud-based systems for dental practices, transitioning to a SaaS model which may impact short-term sales optics but is expected to drive profitable recurring revenue. Management anticipates 2025 results to be more heavily weighted towards the back half of the year, contingent on market share recovery and cost savings. For 2026, key guidance factors will include momentum in high-growth businesses, benefits from restructuring, KKR's impact, new product uptake like the TaberPro conical implant, and overall dental market growth, which has recently been flat to 1%. The company also plans to launch its new global e-commerce platform in the US in Q3, following its successful deployment in the UK and Ireland.

Key Decisions for Investors

• Investors should monitor Henry Schein's progress in achieving its target of 60% operating income from high-growth areas by 2027 and the realization of projected $75-$100 million in restructuring cost savings, as these are key to its earnings growth ambitions.
• Consider the company's accelerated share repurchase activity ($161 million in Q1) as a signal of management's belief in the stock's undervaluation, but weigh this against the back-half weighted earnings expectation for 2025 and the ongoing recovery from the prior cyber incident.
• Evaluate the impact of the KKR collaboration on margin improvements and the uptake of new digital offerings, including the global e-commerce platform and Henry Schein One's cloud-based systems, as crucial drivers for future performance and market differentiation.